PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have emerged as a cornerstone of treatment for advanced NSCLC (5).